Study Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving Chemotherapy-Induced Peripheral Neuropathy Induced by a Common Anticancer Agent
Early findings demonstrated in female rats may one day lead to reductions in the neuropathic pain experienced by millions of breast and ovarian cancer patients and survivors
University of Iowa researchers have published a study in the prestigious Journal of the International Association for the Study of Pain showing that a next-generation form of vitamin B3 called nicotinamide riboside (NR) ameliorates chemotherapy-induced peripheral neuropathy (CIPN) in an animal model. Results from this study suggest that NR may be an effective therapy in relieving CIPN in humans. Access to the study was made available online on February 11, 2017.
Led by Donna Hammond, Ph.D., the research team at the University of Iowa demonstrated that treatment with NR increased blood levels of nicotinamide adenine dinucleotide (NAD+) by 50 percent after three weeks of daily administration. NR was able to prevent the development of tactile hypersensitivity induced by the chemotherapeutic paclitaxel and reverse well-established tactile hypersensitivity, while also blunting escape/avoidance behaviors. Furthermore, the prophylactic effect was sustained for at least two weeks after treatment with NR ceased.
The elements that made this study unique
Marta Hamity, Ph.D., the lead study author, indicated that the team embarked on the study based on evidence that suggested that increasing levels of NAD+ in the cells may protect against neuronal injury. The study used female Sprague-Dawley rats, clinically relevant doses of paclitaxel and incorporated measures that quantify the impact of CIPN on quality of life.
This may one day signal a new approach to alleviating CIPN
“This is significant because the pain associated with CIPN can increase as the [chemotherapy] dose escalates, and at times it reaches a point where the patient is no longer able to tolerate the effective doses,” explained Hammond. “The American Society of Clinical Oncology has issued a position paper that there is an unmet need for treatments that can alleviate CIPN,” stated Hammond. “This study has provided positive data which is particularly exciting considering the unmet need for therapies in this area. We believe that further development of NR as a therapy for CIPN is warranted.”
NR has been the subject of nearly 200 peer-reviewed journal publications and is currently at the center of over 100 collaborative studies between the manufacturer of NR and leading universities and research institutions around the world such as the National Institute of Aging, MIT and the Scripps Research Institute representing an estimated $40-50 million in NR research.
Additional research about NR can be found at www.AboutNR.com.